文献速递肿瘤 PET/CT核素与放射性配体治疗

肺神经内分泌肿瘤的诊疗一体化

Theranostics in Lung Neuroendocrine Tumors.
PubMed 文献 · Semin Nucl Med · 2025-03-06

本文综述肺神经内分泌肿瘤(LNETs)诊疗一体化策略的已有证据。生长抑素受体(SSTR)在神经内分泌肿瘤中高表达,针对SSTR的高特异性放射性药物可用于诊断与治疗。LNETs管理仍存在明显不确定性,新靶点有望在未来发挥作用。

要点

  • LNETs是神经内分泌肿瘤中需从诊断和治疗两方面特殊考虑的常见部位。
  • 诊疗一体化利用共享同一肿瘤靶点的一对诊断与治疗药物,以精准治疗并减少副作用为目标。
  • SSTR在神经内分泌肿瘤中高表达,针对SSTR的高特异性放射性药物已用于诊断和治疗。

核心结论

  • 针对SSTR的高特异性放射性药物出现后,LNETs的管理变得不那么具有挑战性。
  • LNETs管理仍存在显著不确定性,新型诊断与治疗策略仍有介入空间。
  • 本文聚焦诊疗一体化策略在LNETs管理中的已有证据,并强调新靶点未来可能具有的应用价值。

研究设计与样本

  • 本文为综述,聚焦诊疗一体化策略在LNETs管理中的已有证据及新靶点的潜在未来作用。

主要发现

  • 胃肠道和胰腺是最常见原发部位,肺神经内分泌肿瘤(LNETs)也常被报告,需在诊断和治疗方面特殊考虑。
  • 生长抑素受体(SSTR)在神经内分泌肿瘤中丰富表达。
  • 针对SSTR的高特异性放射性药物已同时用于诊断和治疗,以及其他靶向治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出LNETs管理仍存在显著不确定性,新型诊断与治疗策略仍有介入空间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the last 2 decades, there has been a noticeable increase in the incidence of neuroendocrine tumors, in part due to improved understanding of pathology and/or availability of more sensitive and accurate diagnostic tests. While gastrointestinal tract and pancreas are the most common sites of origin, lung neuroendocrine tumors (LNETs) are also frequently reported and need special considerations from diagnostic as well as therapeutic aspects. Radiopharmaceutical therapy (Theranostics) is a novel approach which utilizes a pair of diagnostic and therapeutic agents that share a common target on tumor sites. Precise treatment of the disease with minimum side effects is the principal aim of Theranostics. It's a known fact that somatostatin receptors (SSTR) are abundantly expressed in neuroendocrine tumors. With the advent of highly specific radiopharmaceuticals targeting SSTR receptors for both diagnosis as well as treatment and other targeted therapies, management of LNETs has become less challenging. Still, there exists significant ambiguity in relation to management of LNETs with a scope of novel diagnostic and therapeutic strategies to pitch in. This review focuses on the role of established evidence for Theranostics strategies in the management of LNETs and highlights the potential future role of newer targets which would be of promising value in addressing such rare and complex tumor biology.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dev ID, Puranik AD, Trikalinos NA, et al. Theranostics in Lung Neuroendocrine Tumors. Semin Nucl Med. 2025. PMID: 40055049. doi:10.1053/j.semnuclmed.2025.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。